95TiP Gruppo Italiano Mammella (GIM) 10 – CONSENT: A phase III randomized study comparing concurrent versus sequential administration of adjuvant chemotherapy (CT) and aromatase inhibitors (AIs) in post-menopausal patients (pts) with hormone receptor-positive (HR+) early breast cancer (EBC)

Abstract

In pts with HR+ EBC who are candidates to receive adjuvant CT, endocrine therapy (ET) is currently administered following CT completion. This recommendation is based on preclinical and clinical data suggesting a potential negative interaction between tamoxifen and CT when given concomitantly. However, there is no evidence to support this recommendation with the use of modern CT regimens containing taxanes or when AIs are given as adjuvant ET. Therefore, the optimal timing for integrating modern adjuvant CT and ET with AIs has not been defined yet.